Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management
Reads0
Chats0
TLDR
The most important aspects of patient management are a high index of suspicion and a careful history of drug exposure in an individual who presents with acute, often severe thrombocytopenia of unknown etiology.About:
This article is published in Journal of Thrombosis and Haemostasis.The article was published on 2009-06-01 and is currently open access. It has received 280 citations till now.read more
Citations
More filters
Journal ArticleDOI
How do we approach thrombocytopenia in critically ill patients
TL;DR: A practical approach based on the authors' experience is described to guide management of a critically ill patient who develops thrombocytopenia and the risk‐benefit of prophylactic platelet transfusions in this setting is uncertain.
Journal ArticleDOI
Thrombocytopenia: an update
TL;DR: This review article aims to summarize and address appropriate work‐up of the major and/or life‐threatening causes of thrombocytopenia and some of the better‐characterized congenital thromBocy topenias.
Journal ArticleDOI
Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study.
Edeltraut Garbe,Frank Andersohn,Elisabeth Bronder,Abdulgabar Salama,Andreas Klimpel,Michael Thomae,Hubert Schrezenmeier,Martin Hildebrandt,Ernst Späth-Schwalbe,Andreas Grüneisen,Oliver Meyer,Hanife Kurtal +11 more
TL;DR: This study confirms known ITP risks for glycoprotein IIb/IIIa receptor antagonists and sulphonamides and generates signals for several other drugs and vaccines and indicates new onset of ITP should not only direct attention to drugs as possible aetiological agents, but also to vaccines that are known to cause autoimmune phenomena.
Journal ArticleDOI
Drug-induced thrombocytopenia in critically ill patients.
TL;DR: This review focuses on immune-mediated drug-induced thrombocytopenia from medications commonly utilized in the critically ill patient.
Journal ArticleDOI
Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies
TL;DR: A pragmatic approach to the evaluation of perioperative thrombocytopenia is presented and the benefits and risks of preoperative platelet transfusions should be assessed on a patient‐by‐patient basis, and alternatives to Platelet transfusion should be considered.
References
More filters
Journal ArticleDOI
Heparin-induced thrombocytopenia.
Fabrizio Fabris,Guido Luzzatto,Piero Maria Stefani,Bruno Girolami,Giuseppe Cella,Antonio Girolami +5 more
TL;DR: The aim of this article is to review the most recent advances in the field and to give critical guidelines for the clinical diagnosis and treatment of HIT II, the most frequent and dangerous side-effect of heparin therapy.
Journal ArticleDOI
Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity : an explanation for the thrombotic complications of heparin-induced thrombocytopenia
Theodore E. Warkentin,Catherine P.M. Hayward,Lynn K. Boshkov,Aurelio Santos,Jo-Ann I. Sheppard,Arthur P. Bode,John G. Kelton +6 more
TL;DR: Observations indicate that the generation of procoagulant platelet-derived microparticles in vivo is a plausible explanation for the thrombotic complications observed in some patients with heparin-inducedThrombocytopenia.
Journal ArticleDOI
Drug-Induced Immune Thrombocytopenia
TL;DR: The current understanding of pathogenesis is summarized and a guide for diagnosis and management of thrombocytopenia is provided.
Journal ArticleDOI
Drug-Induced Thrombocytopenia: A Systematic Review of Published Case Reports
James N. George,Gary E. Raskob,Shehla Rizvi Shah,Mujahid A. Rizvi,Stephen A. Hamilton,Scott Osborne,Thomas Vondracek +6 more
TL;DR: This systematic review analyzed all published reports of drug-induced thrombocytopenia by using explicit, a priori criteria for establishing levels of evidence of a causal relation to help clinicians better understand the likelihood that a drug will cause throm bocy topenia.
Journal ArticleDOI
Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function.
TL;DR: Fab fragments of certain antibodies against LIBS on integrin alpha IIb beta 3 (platelet glycoprotein IIb-IIIa) block platelet aggregation, and changes in the conformation of this integrin modulate both the specificity and affinity of ligand recognition.
Related Papers (5)
Drug-induced thrombocytopenia: pathogenesis, evaluation, and management
James N. George,Richard H. Aster +1 more